Literature DB >> 15364442

Efficacy of DNA vaccines expressing the type F botulinum toxin Hc fragment using different promoters.

Amit P Jathoul1, Jane L Holley, Helen S Garmory.   

Abstract

DNA vaccines which expressed the Hc fragment of the Clostridium botulinum type F neurotoxin (BoNT/F Hc) fused to a signal peptide downstream of four different eukaryotic promoters were prepared. Subsequently, the immunogenicity of the DNA vaccines and protection afforded in mice against challenge with 10(4) MLD of type F botulinum toxin was evaluated. The DNA vaccine containing the human ubiquitin gene (UbC) promoter induced the highest BoNT/F Hc-specific antibody concentration following two intramuscular immunisations and afforded 90% protection against challenge. The results from this study indicate that the selection of promoter used in DNA vaccination studies may be of importance in designing optimised vaccines.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15364442     DOI: 10.1016/j.vaccine.2004.04.006

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

1.  Induction of protective neutralizing antibody responses against botulinum neurotoxin serotype C using plasmid carried by PLGA nanoparticles.

Authors:  Tinashe B Ruwona; Haiyue Xu; Junwei Li; Diana Diaz-Arévalo; Amit Kumar; Mingtao Zeng; Zhengrong Cui
Journal:  Hum Vaccin Immunother       Date:  2016-02-02       Impact factor: 3.452

2.  Generation of high-titer neutralizing antibodies against botulinum toxins A, B, and E by DNA electrotransfer.

Authors:  C Trollet; Y Pereira; A Burgain; E Litzler; M Mezrahi; J Seguin; M Manich; M R Popoff; D Scherman; P Bigey
Journal:  Infect Immun       Date:  2009-02-23       Impact factor: 3.441

3.  Enhanced potency of replicon vaccine using one vector to simultaneously co-express antigen and interleukin-4 molecular adjuvant.

Authors:  Yao Ma; Huai-Jie An; Xiao-Qi Wei; Qing Xu; Yun-Zhou Yu; Zhi-Wei Sun
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

4.  Immunization of mice with the non-toxic HC50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge.

Authors:  Waleed Mustafa; Fetweh H Al-Saleem; Zidoon Nasser; Rebecca M Olson; Jeffrey A Mattis; Lance L Simpson; Matthias J Schnell
Journal:  Vaccine       Date:  2011-05-05       Impact factor: 3.641

5.  Bioinformatics in new generation flavivirus vaccines.

Authors:  Penelope Koraka; Byron E E Martina; Albert D M E Osterhaus
Journal:  J Biomed Biotechnol       Date:  2010-05-10

6.  Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine.

Authors:  Mingtao Zeng; Qingfu Xu; Md Elias; Michael E Pichichero; Lance L Simpson; Leonard A Smith
Journal:  Vaccine       Date:  2007-09-05       Impact factor: 3.641

7.  Evaluation of a recombinant Hc of Clostridium botulinum neurotoxin serotype F as an effective subunit vaccine.

Authors:  Yun-Zhou Yu; Na Li; Rui-Lin Wang; Heng-Qi Zhu; Shuang Wang; Wei-Yuan Yu; Zhi-Wei Sun
Journal:  Clin Vaccine Immunol       Date:  2008-10-08

8.  A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A.

Authors:  David F Gardiner; Talia Rosenberg; Jerry Zaharatos; David Franco; David D Ho
Journal:  Vaccine       Date:  2009-04-09       Impact factor: 3.641

9.  A multipathogen DNA vaccine elicits protective immune responses against two class A bioterrorism agents, anthrax and botulism.

Authors:  Na Young Kim; Won Rak Son; Min Hoon Lee; Hong Seok Choi; Jun Young Choi; Young Jo Song; Chi Ho Yu; Dong Hyun Song; Gyeung Haeng Hur; Seong Tae Jeong; Sung Youl Hong; Young Kee Shin; Sungho Shin
Journal:  Appl Microbiol Biotechnol       Date:  2022-02-10       Impact factor: 4.813

Review 10.  Vaccines against Botulism.

Authors:  Grace Sundeen; Joseph T Barbieri
Journal:  Toxins (Basel)       Date:  2017-09-02       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.